Trials / Completed
CompletedNCT00603642
P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
A Randomized, Double Blind, Placebo Controlled Phase 3 Study Evaluating the Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of AMG 531 compared with placebo in thrombocytopenic Japanese subjects with immune (idiopathic) thrombocytopenic purpura (ITP) .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Subcutaneously administered, once a week, for 12 weeks |
| DRUG | AMG 531 | Subcutaneously administered, once a week, for 12 weeks |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2009-04-13
- Completion
- 2009-04-13
- First posted
- 2008-01-29
- Last updated
- 2022-11-08
- Results posted
- 2010-12-10
Source: ClinicalTrials.gov record NCT00603642. Inclusion in this directory is not an endorsement.